Current and future status of prostate cancer chemoprevention.
about
IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer.Contribution of cancer stem cells to tumor vasculogenic mimicry.Advanced research on vasculogenic mimicry in cancerRas guanyl nucleotide releasing protein 2 affects cell viability and cell-matrix adhesion in ECV304 endothelial cells.Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.The role of TG2 in ECV304-related vasculogenic mimicry.
P2860
Current and future status of prostate cancer chemoprevention.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Current and future status of prostate cancer chemoprevention.
@ast
Current and future status of prostate cancer chemoprevention.
@en
type
label
Current and future status of prostate cancer chemoprevention.
@ast
Current and future status of prostate cancer chemoprevention.
@en
prefLabel
Current and future status of prostate cancer chemoprevention.
@ast
Current and future status of prostate cancer chemoprevention.
@en
P2093
P2860
P356
P1476
Current and future status of prostate cancer chemoprevention.
@en
P2093
Masayoshi Nomura
Naohiro Fujimoto
Tetsuro Matsumoto
P2860
P356
10.1586/14737140.6.1.59
P577
2006-01-01T00:00:00Z